News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carrington Laboratories, Inc. (CARN) Subsidiary DelSite Biotechnologies, Inc. Extends Commercial Evaluation License Agreement With National Institutes of Health (NIH) for Typhoid Vaccine



5/16/2008 11:21:11 AM

IRVING, Texas, May 16, 2008 (PRIME NEWSWIRE) -- Carrington Laboratories, Inc. (OTCBB:CARN) today announced its wholly-owned subsidiary, DelSite Biotechnologies, Inc., has extended its Commercial Evaluation License from NIH (National Institutes of Health) for evaluating a novel synthetic typhoid polysaccharide vaccine technology with DelSite's proprietary high-molecular-weight ionic polysaccharide, GelSite(r) polymer. DelSite Biotechnologies, Inc. is developing and commercializing GelSite polymer as a controlled-release drug delivery technology for protein/peptide therapeutics and vaccine products. This synthetic typhoid vaccine represents a unique and important application of the GelSite polymer.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES